Propanc Biopharma, Inc. cash flow statement PPCB

In Q4 of fiscal 2026, the quarter ended Jun 30, 2026, Propanc Biopharma, Inc. used $1.6 million of cash from operations, down 1637.8% from the same quarter a year earlier. It spent $21 on capital expenditures. Free cash flow was negative, at -$1.6 million.

USD in millions, except per-share amounts and ratios. The percent under a figure is the change from the same quarter a year earlier.

Line
Q4 FY2026
Jun 30, 2026
Q3 FY2026
Mar 31, 2026
Q2 FY2026
Dec 31, 2025
Q1 FY2026
Sep 30, 2025
Q4 FY2025
Jun 30, 2025
Q3 FY2025
Mar 31, 2025
Q2 FY2025
Dec 31, 2024
Q1 FY2025
Sep 30, 2024
Operating
Depreciation and amortization
0
0
+544.9%
0
+100.9%
0
-6.7%
—
—
—
—
Stock-based compensation
1
-60.6%
2
+17.8%
2
3
3
2
—
—
Operating cash flow
-2
-1637.8%
-1
-1087.6%
-1
-5434.7%
-2
-723.3%
-0
+64.5%
-0
+6.4%
0
+107.8%
-0
+29.4%
Investing
Capital expenditures
0
0
0
0
—
—
—
—
Investing cash flow
-0
-0
-0
-0
—
—
—
—
Financing
Financing cash flow
2
+2626.7%
1
+565.6%
1
+1660.6%
3
+1071.4%
0
-71.0%
0
+121.3%
0
-80.0%
0
-38.4%
Change in cash
Net change in cash
0
+1104.1%
-0
-425.3%
-0
-873.5%
1
+5098.3%
-0
-360.2%
0
+155.2%
0
-91.7%
-0
-245.3%
Free cash flow
-2
-1
-1
-2
—
—
—
—
Per share
Free cash flow per share
—
-0.05
-0.07
-0.16
—
—
—
—
How these figures are calculated

Quarterly columns are single-quarter amounts. When a 10-Q reports only a year-to-date total, as cash flow statements do, the quarter is that total minus the previous quarter's year-to-date total. The fourth quarter is the annual report's full year minus the first nine months. A column marked YTD is a year-to-date total, shown when the earlier report needed for the single quarter is missing. USD in millions, except per-share amounts and ratios. Capital expenditures, debt repaid, dividends, and buybacks are positive amounts. Investing and financing cash flow keep the filing sign, so an outflow is negative. Free cash flow is operating cash flow minus capital expenditures. Returned to shareholders is dividends plus buybacks. Free cash flow margin, capital expenditures, and stock-based compensation are divided by revenue. Cash conversion is operating cash flow divided by net income. More on our methodology.

Company profile

Industry
Pharmaceutical Preparations (SIC 2834)
Listed as
PPCB (Nasdaq)
Fiscal year ends
June 30
Incorporated in
DE
Headquarters
Camberwell, Victoria, Australia
SEC filer status
Non-accelerated filer, Smaller reporting company
SEC CIK
1517681
Former names
Propanc Health Group Corp (until Apr 5, 2017)

Other Pharmaceutical Preparations companies

Source: SEC EDGAR filings. This is company-reported data, not investment advice.